Department of Hematology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China.
Department of Pathology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China.
Cancer Biomark. 2017;18(4):339-347. doi: 10.3233/CBM-160126.
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is an obviously heterogeneous and highly invasive malignancy without definite phenotype. MicroRNAs (miRNAs) are powerful gene regulators and have been reported as biomarkers in many malignancies.
To discover potential signaling miRNAs in PTCL-NOS distinguished from reactive lymphoid hyperplasia (RLH) and to explore the molecular characteristics based on the discovery.
We measured the expression profile of miRNAs in PTCL-NOS and RLH from our patients using a panel PCR array. We used GO-Analysis to evaluate the function of the targets regulated by the detected miRNAs. Then using pathway enrichment analysis, we defined potential pathways connected with the selected miRNAs.
We found 20 miRNAs which were remarkably up/down-regulated in PTCL-NOS. GO-Analysis and pathway analysis indicated 61 GOs and 34 signaling pathways that were significantly increased or decreased regarding tumorigenesis, tumor progression, invasion, metastasis, and drug resistance.
Briefly, our results suggest that 20 miRNAs have the potential to be used as biomarker for identification of patients with PTCL-NOS.
未特指的外周 T 细胞淋巴瘤(PTCL-NOS)是一种明显异质性和高度侵袭性的恶性肿瘤,没有明确的表型。microRNAs(miRNAs)是强大的基因调控因子,已被报道为许多恶性肿瘤的生物标志物。
发现与反应性淋巴组织增生(RLH)区分的 PTCL-NOS 中潜在的信号 miRNA,并基于发现探索分子特征。
我们使用 PCR 阵列测量了来自我们患者的 PTCL-NOS 和 RLH 中的 miRNA 表达谱。我们使用 GO 分析来评估受检测 miRNA 调控的靶标的功能。然后,通过通路富集分析,我们定义了与选定 miRNA 相关的潜在通路。
我们发现 20 个 miRNA 在 PTCL-NOS 中显著上调/下调。GO 分析和通路分析表明,61 个 GO 和 34 个信号通路在肿瘤发生、肿瘤进展、侵袭、转移和耐药性方面显著增加或减少。
总之,我们的结果表明,20 个 miRNA 有可能作为 PTCL-NOS 患者识别的生物标志物。